Oral talactoferrin extends survival in patients with refractory NSCLC in a randomized, placebo-controlled, phase 2 trial

被引：1

作者：

Parikh, Purvish M.

Wang Yenyun

Ranade, A. A.

Vaid, A. K.

Advani, S. H.

Raghunadharao, D.

Nag, S.

Madhavan, J. P.

Varadhachary, Atul

机构：

[1] Tata Mem Hosp, Bombay 400012, Maharashtra, India

[2] Agennix Inc, Houston, TX USA

[3] Deenanath Mangeshkar Hosp, Pune, Maharashtra, India

[4] Rajeev Gandhi Canc Inst, Delhi, India

[5] Jaslok Hosp, Bombay, Maharashtra, India

[6] Nizams Inst, Hyderabad, Andhra Pradesh, India

[7] Jehangir Hosp, Pune, Maharashtra, India

[8] Reg Canc Ctr, Trivandrum 695011, Kerala, India

[9] Agnenix Inc, Houston, TX USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2007年 / 2卷 / 08期

关键词：

D O I：

10.1097/01.JTO.0000283192.54791.45

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S360 / S360

页数：1

共 50 条

[1] Oral talactoferrin extends survival in patients with refractory NSCLC in a randomized, placebo-controlled, phase 2 trial
Parikh, P. K.
Wang, Y.
Ranade, A. A.
Vaid, A. K.
Advani, S. H.
Raghunadharao, D.
Nag, S.
Madhavan, J. P.
Varadhachary, A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[2] The effect of talactoferrin on overall survival in prognostically important NSCLC subsets in a randomized, placebo-controlled phase II trial.
Parikh, P. M.
Ranade, A.
Vaid, A. K.
Advani, S. H.
Bapna, A.
Zhu, J.
Wang, Y.
Ismail, P. M.
Malik, R. K.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[3] A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Talactoferrin in Patients With Severe Sepsis
Guntupalli, Kalpalatha
Dean, Nathan
Morris, Peter E.
Bandi, Venkata
Margolis, Benjamin
Rivers, Emanuel
Levy, Mitchell
Lodato, Robert F.
Ismail, Preeti M.
Reese, Amber
Schaumberg, John P.
Malik, Rajesh
Dellinger, R. Phillip
CRITICAL CARE MEDICINE, 2013, 41 (03) : 706 - 716
[4] A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
Vollmer, T. L.
Sorensen, P. S.
Selmaj, K.
Zipp, F.
Havrdova, E.
Cohen, J. A.
Sasson, N.
Gilgun-Sherki, Y.
Arnold, D. L.
JOURNAL OF NEUROLOGY, 2014, 261 (04) : 773 - 783
[5] A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
T. L. Vollmer
P. S. Sorensen
K. Selmaj
F. Zipp
E. Havrdova
J. A. Cohen
N. Sasson
Y. Gilgun-Sherki
D. L. Arnold
Journal of Neurology, 2014, 261 : 773 - 783
[6] A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC.
Heymach, JV
Johnson, BE
Rowbottom, JA
Fidias, P
Lu, C
Prager, D
Roubec, J
Csada, E
Dimery, I
Herbst, RS
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 197S - 197S
[7] Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial
Wang, Yong Feng
Tang, Jie Ting
Han, Tao
Ding, Hui Guo
Ye, Wei Jiang
Wang, Mao Rong
Cheng, Jun
Yang, Yong Ping
Chen, Cheng Wei
Xie, Qing
Mao, Qing
Niu, Jun Qi
Wang, Zheng Hua
Wei, Zhong
Chen, Ying Xuan
Zeng, Min De
Mao, Yi Min
JOURNAL OF DIGESTIVE DISEASES, 2018, 19 (03) : 144 - 154
[8] Randomized Controlled Trial of Talactoferrin Oral Solution in Preterm Infants
Sherman, Michael P.
Adamkin, David H.
Niklas, Victoria
Radmacher, Paula
Sherman, Jan
Wertheimer, Fiona
Petrak, Karel
JOURNAL OF PEDIATRICS, 2016, 175 : 68 - +
[9] Anlotinib as 3rd-Line Treatment for Refractory Advanced NSCLC: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
Han, Baohui
Li, Kai
Zhao, Yizuo
Li, Baolan
Cheng, Ying
Zhou, Jianying
Lu, You
Shi, Yuankai
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S177 - S177
[10] RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORAL CA-2+ IN HUMAN HYPERTENSION
MORRIS, CD
HENRY, HJ
MCCARRON, DA
KIDNEY INTERNATIONAL, 1984, 25 (01) : 204 - 204

← 1 2 3 4 5 →